				<u>.</u>						
Form PTO-1449 (Modified) List of Patents and Publications					Atty Docket No. TSC584		Se	erial No.	091224	2/
For Applicant's Information					Applicant	-				,
		Statement	i							
					Zou et al		_			
(Use several sheets if necessary)					Filing Date Group 07/24/98			roup ————		
Re	fer	ence Designat	ion	u	. S. Patent Docu	ments				
Examiner	Γ	Document	}			1			Filing Date	
Initial	<u>ا۔</u>	Number	Date		Name	Clas	s		If Appropriate	
+AP=	-	4,558,579	12/17/85	\rightarrow	Fountain et al	72	+	56		
// /		4,975,282	12/4/90	!	Cullis et al	424	+	450	11/17/87	
<u> </u>	AC	<u> </u>	<u> </u>				_			
	AD	L	<u> </u>				ᆚ			
	AB	İ	<u> </u>			1	\perp			
	AF		i	i		<u>i</u>	\perp		<u> </u>	
	AG		l	Ĭ		ī	ī			
	AH		1	i		Ī	ī			
	AI		i			i	T			
	AJ		1			$\dot{\tau}$	╁			
			<u> </u>			+	-			
	AK						-			
			FOREIGN F	PATE	NT DOCUMENTS					
Examiner		Document	1			1	T		Translation	
Initial		Number	Date		Country	Clas	8	Subclass	Yes/No	
	AL	WO 87/00238	1/16/86		PCT		_			
_//	AM	87/00043	1/15/87		PCT		<u> </u>			» l
III	AN	60-155109	18/15/85		Japanese					//
1/	AO		<u> </u>							. ~
	AP		1	1		1			<u> </u>	1/1
						•	•		•	(
0	THE	R ART (Includ	ing Author,	Ti	tle, Date Pertin	ent P	age	es. Etc.)		
1					ose-dependent Ch					
124		Determined by Radionuclide Angiography After Anthracycline Therapy,"								
70 /	AR	Cancer Treatm. Rep., 62(6):945-948 (1978). Herman et al, "Prevention of Chronic Doxorubicin Cardiotoxicity in								
a '										
1		Beagles by L	<u>iposomal En</u>	ıcap	sulation, " Cance	er Res		<u> 13 : 5427 - 54</u>	<u> 132 (1983). </u>	
	AS									
j		Rahman et al			linical Trial an					
- 1		Liposome-Encapsulated Doxorubicin, " J. Clin. Oncol. 8:1093-1100								
	AT	(1990).								
		Gabizon et al, "Prolonged Circulation Time and Enhanced Accumulation in								
	1	Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-glycol								
		Coated Liposomes, " Cancer Research 54:987-992 (1994).								
Examiner Kull					Date Considered					
EVAMENTE			eronge gene	100	red, whether or	not c	} 	ation is	in conformance	
EXAMINER	5600	nicial II Tel 9: Draw line	erence cons through cit	tati	on if not in cor	lforma	nc	e and not	considered.	
Include	COD	v of this for	m with next	t co	mmunication to a	applic	an	t.,		
			Inf	Eorn	ation Disclosure	Stat	em	entPTO-:		
								A	dded page	

1